Aug 11
25
Several experimental mouse models have shown the effectiveness of treatment for chronic inflammatory diseases of the intestine (MICI), from a derivative of the BCG. A step forward to confirm with clinical trials but which could achieve a treatment against e.g. Crohn’s disease
French researchers have developed a treatment may control certain chronic inflammatory diseases of the intestine (MICI) which particular part Crohn’s disease. Their strategy is based on a derivative of the anti-tuberculosis BCG vaccine. For the time being, the model employed is only experimental, but the runway appears to be ” serious “. Explanations.
The treatment in question was developed by researchers at the Institut Pasteur in Paris and Immunotherapix, a biotechnology company. This derivative of BCG target regulatory T cells. In other words, the cells that ” as well as their name indicates, will regulate the immune system so that it is packaged, as is the case in many inflammatory diseases ” says us Gilles Marchal, main author of this work. The objective is to mobilize a large number, until these cells migrate to inflammatory homes.
Very promising results
At this stage, the strategy seems to work perfectly ” on several experimental mouse models “, says Gilles Marchal. Treatment appears ” very well tolerated, not resulting in very little to no side effects.” “And especially it does not diminish the natural defences of the body “.
Scientists show their confidence, believing that their ” results are very promising .” Next step: the launch of clinical trials on humans. It will however take a bit of patience. Indeed, these tests should not begin before 2013.
